Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
News and updates for Protalix BioTherapeutics, Inc. (PLX) center on its activities as a biopharmaceutical company focused on rare disease therapeutics and recombinant proteins produced with its proprietary ProCellEx® plant cell-based expression system. This page aggregates company press releases, financial announcements and clinical program updates that reflect how Protalix is developing and commercializing enzyme replacement therapies and advancing its pipeline.
Investors and followers of PLX can find coverage of commercial performance for the company’s approved products, including Elfabrio® for Fabry disease and Elelyso® (taliglucerase alfa) for Gaucher disease, supplied to partners such as Chiesi, Pfizer and Fiocruz in Brazil. News items also describe how these established revenue streams support Protalix’s research and development efforts.
Another key theme in Protalix news is pipeline progress. The company regularly reports on PRX–115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout, including Phase 1 data and regulatory milestones like the submission of an IND to the FDA for a planned Phase 2 trial. Updates also cover PRX–119, a long-acting DNase I candidate for NETs-related and rare renal diseases, and the company’s collaboration with Secarna Pharmaceuticals to discover antisense oligonucleotide therapies for rare kidney indications.
Regulatory and corporate developments appear frequently in PLX news, such as EMA evaluations of new dosing regimens for Elfabrio, inclusion in the Russell 3000® and 2000® Indexes, at-the-market equity program amendments, executive appointments and outcomes of stockholder meetings or legal matters. Bookmark this page to follow how Protalix’s commercial partnerships, clinical trials and strategic collaborations evolve over time.
Protalix (NYSE: PLX) provided a stockholder update outlining 2026 priorities: commercial execution through partners, advancement of PRX-115 for uncontrolled gout, and a focused renal pipeline including PRX-119 and an RNA collaboration with Secarna.
Key facts: Phase 1 PRX-115 showed rapid, durable urate lowering to <6 mg/dL with effects lasting up to 12 weeks at higher doses and generally mild tolerability; an IND for Phase 2 became effective and sites are activated. Commercially, Elfabrio launch metrics track to plan via Chiesi and Elelyso sales continue via Pfizer and Fiocruz. A CHMP negative opinion on a 2 mg/kg E4W Elfabrio regimen is under appeal with an outcome expected in Q1 2026.
Protalix (NYSE American: PLX) and Secarna Pharmaceuticals announced a collaboration and option agreement to discover antisense oligonucleotide (ASO) therapies targeting multiple rare renal indications.
Protalix selected biological targets and Secarna will use its OligoCreator® AI platform to design and profile ASO candidates, with the partners aiming to advance programs from preclinical stages toward clinical trials. Secarna grants Protalix an exclusive option for a worldwide, milestone- and royalty-bearing license to develop, market, and commercialize any active compounds from the research.
Protalix BioTherapeutics (NYSE: PLX) reported third-quarter 2025 results and a business update on November 13, 2025. YTD revenue was $43.6 million, up 24% year-over-year; Q3 revenue was $17.9 million, down 1% year-over-year. Q3 net income was ~$2.4 million ($0.03/share); YTD net loss was ~$1.1 million ($0.01/share).
R&D spending rose substantially as the company prepares a phase 2 trial of PRX-115; the company submitted an IND in October 2025 that became effective after the FDA 30-day review. A CHMP negative opinion on an Elfabrio dosing variation led to a re-examination request by Chiesi; the approved 1 mg/kg E2W Elfabrio regimen remains unchanged. Cash and equivalents were $29.4 million, stated sufficient for at least 12 months from the quarterly report date.
Protalix BioTherapeutics (NYSE American: PLX) will release its financial results for the quarter ended September 30, 2025 and provide a business update on November 13, 2025.
Management will host a conference call at 8:00 a.m. Eastern Standard Time with toll-free and international dial-ins and a live webcast. Participants are asked to join 15 minutes early to register and install any required audio software. A replay will be available for two weeks on the company's Investors Events Calendar.
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its ProCellEx® plant cell-based protein expression system, has announced its participation in the upcoming Q3 Investor Summit Virtual.
The company's former Senior Vice President and CFO, Eyal Rubin, will deliver a presentation on September 16, 2025, at 10:30 AM EDT. The presentation will focus on the company's growth strategies and market opportunities, and will be accessible via webcast.
Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in plant cell-based protein expression systems, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dror Bashan will deliver a presentation on Monday, September 8, 2025, at 3:30 PM EDT in the Holmes II Room at the Lotte New York Palace Hotel. The management team will also engage in one-on-one meetings with registered investors throughout the conference.
Protalix BioTherapeutics (NYSE American: PLX) reported strong Q2 2025 financial results, with revenues from goods increasing 16% to $15.4 million compared to Q2 2024. The company achieved net income of $164,000 versus a net loss of $2.2 million in the same period last year. The growth was primarily driven by increased sales of Elfabrio® to Chiesi in the $2.3 billion global Fabry disease market.
Key developments include the appointment of Gilad Mamlok as new CFO effective August 24, 2025, replacing Eyal Rubin, and the company's addition to the Russell 3000® and Russell 2000® Indexes. Protalix plans to initiate a Phase 2 trial for PRX-115, their gout treatment candidate, in Q4 2025. The company ended the quarter with $33.4 million in cash and cash equivalents.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in ProCellEx® plant cell-based protein expression system, will release its Q2 2025 financial results on August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT to discuss financial results and provide corporate and regulatory updates.
The conference call will be accessible via multiple channels, including toll-free numbers for US and Israeli participants, and will feature a convenient Call me™ feature. A webcast replay will be available for two weeks following the presentation on the company's investor relations website.
Protalix BioTherapeutics (NYSE American: PLX) has appointed Gilad Mamlok as its new Senior Vice President and Chief Financial Officer, effective August 24, 2025. Mamlok brings three decades of experience in healthcare and technology companies, with expertise in capital markets, M&A, and business development.
Mamlok will succeed Eyal Rubin, who will remain available to the company until October 2025 to ensure a smooth transition. Mamlok's recent experience includes CFO positions at TytoCare Ltd. and Sol-Gel Technologies Ltd., where he led significant capital markets transactions and licensing deals. He previously worked at Given Imaging, which was acquired by Covidien in 2014.
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in plant cell-based protein expression systems, has announced its addition to the Russell 3000® and Russell 2000® Indexes effective June 27, 2025. This inclusion is part of the 2025 Russell indexes annual reconstitution.
The Russell indexes, which benchmark approximately $10.6 trillion in assets, are widely utilized by investment managers and institutional investors. Membership in these indexes is determined by market capitalization rankings and style attributes, with the Russell 3000® Index capturing the 4,000 largest US stocks as of April 30.